Qilu Announces $235 Million Deal for Cend's Immunotherapy

Qilu Pharma of Jinan formed a $235 million collaboration with San Diego 's Cend Therapeutics to develop and commercialize Cend’s immunotherapy in China . CEND-1 is an investigational drug that modifies the tumor microenvironment. It has a dual mechanism, activating a novel uptake pathway to allow therapeutic drugs into the tumor while it also depletes immunosuppressive cells. CEND-1 is in a Phase II trial to treat pancreatic cancer. Qilu will pay $10 million upfront and up to $225 million in milestones, plus royalties. More details....
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.